November 04, 2025

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

Conexiant

November 03, 2025

Settlement Cash: Misused or Misread?

Opioid settlement funds were used for R&B concerts promoting addiction awareness in Irvington, New Jersey, highlighting broader debates over how opioid restitution money is spent nationwide.

KFF Health News

October 31, 2025

Single-Injection Omvoh Option Simplifies Ulcerative Colitis Care

The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 07, 2025

EASO Issues Obesity Pharmacotherapy Guidance

EASO framework guides obesity drug selection by weight loss effect and complication focus.

Conexiant

January 24, 2025

CRC Risk: Comparing BMI with Central Obesity Metrics

New evidence links central obesity measures to higher colorectal cancer risk compared to body mass index.

Conexiant